RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.4103/2321-0656.187990
Expanding the definition of noncommunicable disease
Publikationsverlauf
Publikationsdatum:
23. November 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00041241/201602/lookinside/thumbnails/10-4103-2321-0656-187990-1.jpg)
Abstract
Noncommunicable diseases (NCDs) are responsible for 68% of all deaths in 2012. Eighty-two percent of these “premature” deaths occurred in low- and middle-income countries. Most of the NCD deaths are caused by cardiovascular diseases, cancer, diabetes, chronic respiratory diseases, mental health, road traffic accidents, and violence. The World Health Organization, several governments, and nongovernmental organizations have taken up numerous programs to curb the menace of NCDs. However, the present programs do not include some common chronic medical conditions which also lead to considerable morbidity and mortality. The present review highlights three important chronic disorders: chronic kidney disease (CKD), liver disease (cirrhosis and nonalcoholic fatty liver), and thyroid diseases. CKD is an internationally recognized public health problem affecting 5–10% of the world population. CKD resulted in 956,000 deaths in 2013 and proposes them to be included in the world wide accepted definition of NCD. Cirrhosis and chronic liver disease were the tenth leading cause of death for men and the twelfth for women in the United States in 2001. Moreover, 4–10% of the global population have thyroid dysfunction. This mini-review proposes to expand the definition of NCD to include these three major illnesses.
-
References
- 1 Noncommunicable Diseases. WHO Fact Sheet: Updated; January, 2015. Available from: http://www.who.int/mediacentre/factsheets/fs355/en/ [Last accessed on 2016 Jun 27].
- 2 Non-communicable diseases deemed development challenge of ‘Epidemic Proportions’ in political declaration adopted during landmark general assembly summit. New York: United Nations: Department of Public Information; 2011. Available from: http://www.un.org/en/ga/ncdmeeting2011/
- 3 The Top 10 Causes of Death. World Health Organization. Available from: www.who.int/mediacentre/factsheets/fs310/en [Last accessed on 2016 Jun 27].
- 4 Noncommunicable Diseasese. World Health Organization. Available from: www.who.int/mediacentre/factsheets/fs355/en/ [Last accessed on 2016 Jun 27].
- 5 Global noncommunicable diseases. Saving lives by reducing risk. Centers for Disease Control and Prevention (CDC); 20 April, 2016. Available from: www.cdc.gov/globalhealth/healthprotection/ncd/ [Last Accessed on 2016 Jul 02].
- 6 Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H. et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the global burden of disease study 2010. Lancet 2012; 380: 2224-2260
- 7 Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE. et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med 2014; 371: 624-634
- 8 World Health Organization. Non-communicable Diseases Country Profile; 2011. Available from: www.who.int/nmh/publications/ncd_profiles2011/en/ [Last accessed on 2016 Jun 27].
- 9 Mahal A, Karan A, Engelgau M. The economic implications of non-communicable disease for India. Washington, DC: The International Bank for Reconstruction and Development/The World Bank; 2009: xiv
- 10 ICMR-MRC Workshop. Building Indo-UK Collaboration in Chronic Diseases. 2009: 16
- 11 Preventing Chronic Diseases a Vital Investment. Geneva: Cataloguing-in-Publication Data (World Health Organization); 2005: 1
- 12 Srinath Reddy K, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet 2005; 366: 1744-1749
- 13 World Health Organization. Chronic Disease Report; 2005. Prakash R. Upadhay from AIIMS, New Delhi published in Iranian J Publ Health 2012; 41: 1-8
- 14 Prevention and Control of Non Communicable Diseases. Ministry of Health & Family Welfare-Government of India. Available from: http://www.mohfw.nic.in [Last accessed on 2016 Jul 02].
- 15 Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N. et al. The burden of kidney disease: Improving global outcomes. Kidney Int 2004; 66: 1310-1314
- 16 Martínez-Castelao A, Górriz JL, Segura-de la Morena J, Cebollada J, Escalada J, Esmatjes E. et al. Consensus document for the detection and management of chronic kidney disease. Nefrologia 2014; 34: 243-262
- 17 GBD Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the global burden of disease study 2013. Lancet 2015; 385: 117-171
- 18 Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M. et al. Guidelines for the management of chronic kidney disease. CMAJ 2008; 179: 1154-1162
- 19 Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors – United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007; 56: 161-165
- 20 Morgan T. Chronic kidney disease (stages 3–5) prevalence estimates using data from the Neoerica study (2007). England: Association of Public Health Observatories; 2009
- 21 Agarwal SK, Dash SC, Irshad M, Raju S, Singh R, Pandey RM. Prevalence of chronic renal failure in adults in Delhi, India. Nephrol Dial Transplant 2005; 20: 1638-1642
- 22 Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Public Health 2008; 8: 117
- 23 Anderson RN, Smith BL. Deaths: Leading causes for 2001. Natl Vital Stat Rep 2003; 52: 1-85
- 24 Sørensen HT, Thulstrup AM, Mellemkjar L, Jepsen P, Christensen E, Olsen JH. et al. Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: A nationwide cohort study in Denmark. J Clin Epidemiol 2003; 56: 88-93
- 25 Shaker M, Tabbaa A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: New challenges and new opportunities. World J Gastroenterol 2014; 20: 5320-5330
- 26 Rinella ME. Nonalcoholic fatty liver disease: A systematic review. JAMA 2015; 313: 2263-2273
- 27 Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Bethesda, MD: American Gastroenterological Association; 2002
- 28 Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 2015; 41: 65-76
- 29 Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H. et al. Fatty liver in non-alcoholic non-overweight Japanese adults: Incidence and clinical characteristics. J Gastroenterol Hepatol 2002; 17: 1098-1105
- 30 Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population – Examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12: 593-597
- 31 Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH. et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: An epidemiological survey. World J Gastroenterol 2003; 9: 1106-1110
- 32 Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E. et al. Non-alcoholic fatty liver disease and mortality among US adults: Prospective cohort study. BMJ 2011; 343: d6891
- 33 Clark JM, Diehl AM. Nonalcoholic fatty liver disease: An underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289: 3000-3004
- 34 McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 521-533 viii.
- 35 Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR. et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010; 51: 1593-1602
- 36 Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. Prevalence of non-alcoholic fatty liver disease in urban South Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 2009; 84: 84-91
- 37 Ingle M, Abraham P. Epidemiology of non-alcoholic fatty liver disease in Asia. Non-alcoholic fatty liver disease: A clinical spectrum. In: Choudhuri G. ECAB Clinical Update: Gastroenterology/Hepatology. New Delhi: Elsevier; 2013: 18-28
- 38 Usha Menon V, Sundaram KR, Unnikrishnan AG, Jayakumar RV, Nair V, Kumar H. High prevalence of undetected thyroid disorders in an iodine sufficient adult South Indian population. J Indian Med Assoc 2009; 107: 72-77
- 39 Marwaha RK, Tandon N, Karak AK, Gupta N, Verma K, Kochupillai N. Hashimoto's thyroiditis: Countrywide screening of goitrous healthy young girls in postiodization phase in India. J Clin Endocrinol Metab 2000; 85: 3798-3802
- 40 Hollowell JH, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA. et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489-499
- 41 Olsen AH, Kelsberg G, Coffey J, Hsu JT. Clinical inquiries. Should we screen women for hypothyroidism?. J Fam Pract 2004; 53: 653-655
- 42 Demitrost L, Ranabir S. Thyroid dysfunction in type 2 diabetes mellitus: A retrospective study. Indian J Endocrinol Metab 2012; 16 (Suppl. 02) S334-S335
- 43 Brenta G. Diabetes and thyroid disorders. Br J Diabetes Vasc Dis 2010; 10: 172-177
- 44 Duntas LH, Orgiazzi J, Brabant G. The interface between thyroid and diabetes mellitus. Clin Endocrinol (Oxf) 2011; 75: 1-9